Why the Orthocell (ASX:OCC) share price is on the rise

The Orthocell Ltd (ASX: OCC) share price is rising after the company announced an earlier than expected positive update. Here's a closer look.

| More on:
Surge in ASX share price represented by happy woman pointing to her big smile

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are edging higher in mid-afternoon trade after the company announced it has been recommended for inclusion on the Australian Prosthesis List. At the time of writing, the Orthocell share price has risen 3.85% to 54 cents.

What's driving the Orthocell share price?

Investors appear to be pleased with the latest news from the company, pushing the Orthocell share price higher on Friday.

According to its release, Orthocell advised it has received word from the Australian Government Department of Health, that its CelGro Dental product has been recommended for inclusion on the Australian Prosthesis List.

Once on the list, this allows the company to be reimbursed for its products by private health insurance agencies when patients have hospital cover. In a way, it acts as an incentive program that can further promote the take up on CelGro Dental.

Originally, Orthocell expected to be included on the Prosthesis List sometime between the middle and the end of FY21. However, with the date significantly brought forward, the company could achieve its inclusion within the first quarter of the 2021 calendar year.

Orthocell stated that the latest update further advances its position in securing a global distribution partner.

Quick take on CelGro

Orthocell's lead product, CelGro, facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. This includes treating defects in areas of the body such as tendons, bones, nerves, and cartilage.

Most notably, the collage medical device can be used in dental bone and tissue regeneration procedures. These include dental bone repairs, growth around dental implants in extraction sockets, and tissue regeneration in intrabony defects.

Words from the managing director

Orthocell managing director Paul Anderson hailed the importance of today's update. He said:

Inclusion on the prothesis list is an important step in gaining reimbursement from private insurers for Striate + (previously named CelGro Dental). This is a significant milestone for our Company that is made possible by our recent Australian TGA approval and clinical data enabling progression towards reimbursement.

How has the Orthocell share price performed lately?

The Orthocell share price has been tracking higher since the start of November, up around 65% over the last three months.

Orthocell shares reached a 52-week high mid-last month on the back of receiving regulatory approval for entry to the United States market.

Based on the current Orthocell share price, the company commands a market capitalisation of roughly $101 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Share Market News

Telstra share price hits 8-year high amid a lacklustre trading week

The ASX 200 communications services sector was the best performer last week, rising 2.96%.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »